CONCORD DRUGS
|
The Current P/E Ratio of CONCORD DRUGS is 46.97.
| Share Price | ₹73.0 | Nov 12,2026 |
| Market Cap | ₹96.3 Cr | |
| Earnings-TTM | ₹2.1 Cr | TTM-Consolidated Results |
| Price/Earnings | 46.97x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of CONCORD DRUGS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹96.3 Cr] as on Nov 12,2026
(/) Earnings [ ₹2.1 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 46.97x ]
Thus, for CONCORD DRUGS , the investors are currently willing to pay 46.97 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of CONCORD DRUGS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of CONCORD DRUGS over the last five years.
Historical PE (Price/Earnings) ratio chart of CONCORD DRUGS
PE Ratio Performance Analysis for CONCORD DRUGS
- CONCORD DRUGS 's p/e ratio for fiscal years ending Mar2025 to Mar2022 averaged 52.19x.
- CONCORD DRUGS 's operated at median p/e ratio of 74.45x from fiscal years ending March 2018 to 2022.
- Looking back at the last 4 fiscal years, CONCORD DRUGS 's p/e ratio peaked in Mar2025 at 92.44x.
- CONCORD DRUGS 's p/e ratio hit its five-year low in Mar2022 of 15.9x.
How does CONCORD DRUGS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| CONCORD DRUGS | 2.05 | 46.97 | 96.3 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,037.20 | 41.02 | 452,707.0 |
| DIVIS LABORATORIES LTD | 3,363.00 | 90.38 | 303,962.0 |
| TORRENT PHARMACEUTICALS LTD | 2,099.00 | 85.51 | 179,494.0 |
| CIPLA LTD | 2,868.29 | 39.71 | 113,912.0 |
| DR REDDYS LABORATORIES LTD | 2,759.70 | 41.95 | 115,769.0 |
| MANKIND PHARMA LTD | 2,249.69 | 48.38 | 108,837.0 |
| LUPIN LTD | 5,221.47 | 17.64 | 92,098.8 |
| ZYDUS LIFESCIENCES LTD | 4,159.00 | 28.91 | 120,249.0 |
| AUROBINDO PHARMA LTD | 3,993.05 | 26.01 | 103,856.0 |
| LAURUS LABS LTD | 1,333.75 | 97.03 | 129,410.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs CONCORD DRUGS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 17.64x |
| Max industry PE | 97.03x |
| Median industry PE | 41.95x |
| Average industry PE | 51.23x |
You may also like the below Video Courses